Quality-of-life results of an EORTC phase III randomized trial of adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases of solid tumors

被引：6
|
作者：
Soffietti, R.
Mueller, R. P.
Abacioglu, M. U.
Villa, S.
Fauchon, F.
Baumert, B.
Fariselli, L.
Tridello, G.
Kocher, M.
Bottomley, A.
机构：
[1] Univ Turin, Turin, Italy
[2] S Giovanni Battista Hosp, Turin, Italy
[3] Univ Cologne, D-50931 Cologne, Germany
[4] Marmara Univ, Istanbul, Turkey
[5] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[6] Ctr Haute Energie, Nice, France
[7] UMC, MAASTRO GROW Res Inst, Maastricht, Netherlands
[8] Fdn Ist Neurol, Milan, Italy
[9] European Org Res Treatment Canc, Brussels, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.9036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9036
引用
收藏
页数：1
相关论文
共 47 条
  • [41] Radiation-related Quality of Life Parameters after Targeted Intraoperative Radiotherapy vs. Whole Breast Radiotherapy in Patients with Breast Cancer: Results from the Randomized Phase III Trial TARGIT-A
    Welzel, G.
    Boch, A.
    Blank, E.
    Kraus-Tiefenbacher, U.
    Keller, A.
    Hermann, B.
    Suetterlin, M.
    Wenz, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S206 - S207
  • [42] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    Bottomley, Andrew
    Coens, Corneel
    Mierzynska, Justyna
    Blank, Christian U.
    Mandala, Mario
    Long, Georgina, V
    Atkinson, Victoria G.
    Dalle, Stephane
    Haydon, Andrew M.
    Meshcheryakov, Andrey
    Khattak, Adnan
    Carlino, Matteo S.
    Sandhu, Shahneen
    Puig, Susana
    Ascierto, Paolo A.
    Larkin, James
    Lorigan, Paul C.
    Rutkowski, Piotr
    Schadendorf, Dirk
    Koornstra, Rutger
    Hernandez-Aya, Leonel
    Di Giacomo, Anna Maria
    van den Eertwegh, Alfonsus J. M.
    Grob, Jean-Jacques
    Gutzmer, Ralf
    Jamal, Rahima
    van Akkooi, Alexander C. J.
    Krepler, Clemens
    Ibrahim, Nageatte
    Marreaud, Sandrine
    Kicinski, Michal
    Suciu, Stefan
    Robert, Caroline
    Eggermont, Alexander M. M.
    LANCET ONCOLOGY, 2021, 22 (05): : 655 - 664
  • [43] Randomized phase III trial of prophylactic cranial irradiation versus observation in patients with fully resected stage IIIA-N2 nonsmall-cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy
    Li, N.
    Zeng, Z. -F.
    Wang, S. -Y.
    Ou, W.
    Ye, X.
    Li, J.
    He, X. -H.
    Zhang, B. -B.
    Yang, H.
    Sun, H. -B.
    Fang, Q.
    Wang, B. -X.
    ANNALS OF ONCOLOGY, 2015, 26 (03) : 504 - 509
  • [44] Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
    Coens, Corneel
    Suciu, Stefan
    Chiarion-Sileni, Vanna
    Grob, Jean-Jacques
    Dummer, Reinhard
    Wolchok, Jedd D.
    Schmidt, Henrik
    Hamid, Omid
    Robert, Caroline
    Ascierto, Paolo A.
    Richards, Jon M.
    Lebbe, Celeste
    Ferraresi, Virginia
    Smylie, Michael
    Weber, Jeffrey S.
    Maio, Michele
    Bottomley, Andrew
    Kotapati, Srividya
    de Pril, Veerle
    Testori, Alessandro
    Eggermont, Alexander M. M.
    LANCET ONCOLOGY, 2017, 18 (03): : 393 - 403
  • [45] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
    Bottomley, A.
    Kicinski, M.
    Long, G. V.
    Mandala, M.
    Atkinson, V. G.
    Blank, C. U.
    Haydon, A. M.
    Dalle, S.
    Khattak, A.
    Carlino, M. S.
    Meshcheryakov, A.
    Sandhu, S. K.
    Puig Sarda, S. S.
    Coens, C.
    Suciu, S.
    Grebennik, D.
    Krepler, C.
    Lorigan, P.
    Robert, C.
    Eggermont, A. M. M.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1410 - S1411
  • [46] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
    Buehrer, Emanuel
    Kicinski, Michal
    Mandala, Mario
    Pe, Madeline
    Long, Georgina, V
    Atkinson, Victoria
    Blank, Christian U.
    Haydon, Andrew
    Dalle, Stephane
    Khattak, Adnan
    Carlino, Matteo S.
    Meshcheryakov, Andrey
    Sandhu, Shahneen
    Puig, Susana
    Schadendorf, Dirk
    Jamal, Rahima
    Rutkowski, Piotr
    van den Eertwegh, Alfonsus J. M.
    Coens, Corneel
    Grebennik, Dmitri
    Krepler, Clemens
    Robert, Caroline
    Eggermont, Alexander
    LANCET ONCOLOGY, 2024, 25 (09): : 1202 - 1212
  • [47] Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapya European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)
    Coens, Corneel
    van der Graaf, Winette T. A.
    Blay, Jean-Yves
    Chawla, Sant P.
    Judson, Ian
    Sanfilippo, Roberta
    Manson, Stephanie C.
    Hodge, Rachel A.
    Marreaud, Sandrine
    Prins, Judith B.
    Lugowska, Iwona
    Litiere, Saskia
    Bottomley, Andrew
    CANCER, 2015, 121 (17) : 2933 - 2941
12345